SAFETY PROFILE OF COVID-19 VACCINES IN PREGNANT AND POSTPARTUM WOMEN IN BRAZIL

- 2 Authors names: Yaping Qiao PhD*1, Ariane de Jesus Lopes de Abreu MSc*2, Carolina Zampirolli Dias
- 3 MSc², Xing Meng PhD¹, Rafaela Vansan Ferreira BSc², Ramon Gonçalves Pereira MSc², Guilherme Silva
- 4 Julian MSc², Weidong Yin MBA¹
- * Y.P.Q. and A.J.L.A contributed equally to this article.
- 6 Affiliations and full addresses:
- ¹ Sinovac Biotech Co, Ltd, Beijing, P.R. China; qiaoyp6109@sinovac.com (Y.P.Q.); mengx@sinovac.com
- 8 (X.M.); yinwd@sinovac.com (W.D.Y.)
- 9 ²IQVIA Brazil, São Paulo 04719-002, SP, Brazil; ariane.dejesuslopesdeabreu@igvia.com (A.J.L.A.);
- 10 carolina.zampirolli@iqvia.com (C.Z.D.); rafaela.ferreira@iqvia.com (R.V.F.); rpereira2@br.imshealth.com
- 11 (R.G.P.); guilherme.julian@iqvia.com (G.S.J.)
- 13 Corresponding Author:
- 14 Weidong Yin

1

12

17

19 20

21

22

23

24

25

26

27

28

29

30

31 32

33

34

35

36

- 15 Sinovac Biotech Co, Ltd, No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, Beijing, P.R. China,
- 16 yinwd@sinovac.com

18 Abstract

Background: Although COVID-19 vaccines are currently under use in pregnant and postpartum women, there is still lack of evidence regarding safety and effectiveness in these populations. This study aims to describe the safety profile of COVID-19 vaccines in pregnant and postpartum women in the early stage of vaccination campaign in Brazil. Methods: This is an observational cross-sectional study using data from the Brazilian surveillance information system for adverse events (SI-EAPV) to characterize the safety of COVID-19 vaccines available (Sinovac/Butantan, Pfizer/BioNTech, AstraZeneca and Janssen) in Brazilian pregnant and postpartum women after receiving it from April to August 2021. A descriptive analysis was performed to assess the frequency and incidence rate of the adverse events (AE) for COVID-19 vaccines. Results: A total of 3,333 adverse events following COVID-19 immunization were reported for the study population in the SIEAPV. The incidence of AE found was 309.4/100,000 doses (95% CI 297.23, 321.51). Regarding the four vaccines available in the country, Sinovac/Butantan had the lowest incidence (74.08/100,000 doses; 95% CI 63.47, 84.69). Systemic events were the most frequent notified for the group (82.07%), followed by local (11.93%) and maternal (4.74%), being most of them classified as non-severe (90.65%). Conclusion: A similar pattern of AE as stated in other studies was found, with even better results for non-viral vector vaccines, corroborating to the recommendation of vaccination for these groups. Even though, further studies appraising a longer observation time are still needed to provide a broader safety aspect for the vaccines currently under use for this population.

Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

The Coronavirus disease 2019 (COVID-19) has been shown to be less lethal than previous coronavirus diseases, although it is highly contagious. Also, a higher risk of severe disease has been associated with aging and comorbidities. Equally important increased risk has been noted in pregnant and postpartum women, making them particularly vulnerable to COVID-19.1 Studies have shown that, when compared to non-pregnant, pregnant women might develop more severe symptoms, being at increased risk of requiring hospitalization in intensive care unit, along with invasive ventilation, extra corporeal membrane oxygenation and mortality. ^{2,3} In Brazil, more than 18 thousand cases of severe acute respiratory syndrome (SARS) by COVID-19 were recorded in pregnant and postpartum women, resulting in almost 1,500 deaths by June 2021. Likewise, a 20% increase in maternal mortality rate was observed in 2020.4 Until now, there is still lack of evidence regarding safety and efficacy of the vaccines in pregnant and postpartum women, since they were not in included in initial studies of COVID-19 vaccines. ⁵ Even though, considering their higher susceptibility to COVID-19, vaccination for this group has been conducted by assessing risks and benefits. 6 COVID-19 immunization started on January 2021 in Brazil and, in March 2021, pregnant and postpartum women with comorbidities were defined as priority group. In April 2021, Ministry of Health (MoH) recommended that this subgroup should be vaccinated, as long as a careful assessment was carried out with the physician, regardless of the gestational age. 7 Due to adverse events experience by this subgroup, in May 2021 vaccination was changed again only for those women with comorbidity, and, in July 2021, changed to include the entire maternal population. Four COVID-19 vaccines were initially recommended - Sinovac/Butantan, Janssen, AstraZeneca and Pfizer/BioNTech, although after May 2021 there was a recommendation to remain only Sinovac/Butantan and Pfizer/BioNTech vaccines for this group^{8,9}

By November 2021, about 1,7 million doses have been administered in this group, with an estimative to vaccinate more than 2,5 million pregnant and postpartum women in the country. ^{8,10} Post authorization safety studies are a way to provide more evidence for this population. However, up to now, there are few evidence regarding the safety profile of those vaccines for pregnant and postpartum women from real world evidence perspective, considering pharmacovigilance systems as main source of information, especially for low and middle-income countries (LMIC), such as Brazil. ¹¹ In that way, this study aims to describe the incidence of adverse events (AE) reported by pregnant and postpartum women after receiving vaccines approved for use in the early stage of vaccination campaign (April 2021 to August 2021) in Brazil.

Methods

Surveillance Systems and Covered Population

In Brazil, records of adverse events following immunization (AEFI) in vaccinated individuals in the public services are made available by the General Coordination of the National Immunization Program (NIP). The NIP is responsible for the registration, investigation and causality analysis of AEFI reported by the public health system. For this study we requested the SI-EAPV (AEFI Surveillance Information System) dataset to the Brazilian MoH, using the Fala BR platform (https://www.gov.br/acessoainformacao/pt-br/falabr). This system is linked to the national system for reporting AE related to the use of drugs and vaccines in VigiMed, adopted at the end of 2018 by Anvisa, as a result of its partnership with the Uppsala Monitoring Centre (UMC). The SI-EAPV has the purpose to systematically monitor the notifications, investigate and consolidate data relating to AEFI occurring at the National, State, Regional, Municipal and local levels, contributing to improve the safety in the use of immunizations, with a passive surveillance approach. Following the stablished flow, during the COVID-19 pandemic, all AEFI related to COVID-19 vaccines have been notified in SI-EAPV. To assess the total number of vaccines doses administered in the country, the National Vaccination Campaign against COVID-19 database

85

86

87

88

89

90

91

92

93

94 95

96

97

98

99

100

101

102

103

104

105

106

107

("Campanha Nacional de Vacinação contra a COVID-19"), from OpenDatasus, were used. 16 This dataset is updated daily and, for this study, we used data from 3 November 2021. Pregnant women were identified in the datasets as those who reported to be pregnant at the time they received the vaccine and postpartum were considered those women who reported to be breastfeeding in the SI-EAPV and who declared to be at postpartum at the moment of the vaccination. Registries of AEFI with more than 50% of variables with missing data were excluded from the study. Quality check procedures within the dataset were performed; this led to the exclusion of São Paulo State from the analysis to minimize potential selection and information bias since the data was underreported. Study setting and outcomes We analyzed AEFI notifications reported by pregnant and postpartum women who received any COVID-19 vaccine authorized and available in Brazil for use. AEFI could be reported as adverse event (AE) or immunization error (IE), after receiving at least one dose of a COVID-19 vaccine, including: CoronaVac (Sinovac/Butantan), Ad26.COV2.S (Janssen), ChAdOx1 nCoV-19 and BBV152 (AstraZeneca) and/or BNT162b2 (Pfizer/BioNTech). Demographic characteristics were described according to the age, race/ethnicity, region of the country where the notification was reported and the maternal situation of the woman. The AE were described according to the type (local, systemic and maternal)¹⁷, severity (severe and non-severe) as well as the case evolution (death, under investigation, cure without sequelae, unknown/ loss of follow-up and under investigation). AE reported as "COVID-19", "PCR positive to COVID-19" and the like were classified as inconclusive and those reported as "vaccination error", "inadvertent exposure to vaccine", "contraindication" was classified as inconsistent.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

Additionally, considering that MoH changed the recommendation to vaccinate this groups only with vaccines that do not contain viral vector, the same woman could have received different vaccines as first and second dose.^{7,8} Statistical Analysis Description of AE notifications characteristics were performed for women reporting to be pregnant or at postpartum after receiving a COVID-19 vaccine from April to August 2021. AE were presented as number and frequency (%) for the outcomes of interest. The incidence rate (IR) of AE per 100,000 doses applied was also estimated with 95% confidence interval (CI). IR was calculated dividing the number of AE notified during the period of the study by the number of doses administered in the same group in the same period. Data analyses were conducted using Python version 3.6.5 (Python Software Foundation). Datasets used were public and anonymized, protecting the confidentiality and privacy of all patients. 18 All activities were conducted according to the applicable federal laws. 19 Results From April to August 2021, a total of 3,333 AEFI reported by Brazilian pregnant and postpartum women who received COVID-19 vaccines in the SI-EAPV were included in the study. Of those, 473 were from women who received Sinovac/Butantan, 788 Pfizer/BioNTech, 2,016 AstraZeneca and 56 Janssen (Figure 1). AE was the most common reported AEFI by this population (74.59%). Regarding IE, they were reported in 25.29% of the notifications, being more frequent among pregnant and postpartum women who received Sinovac/Butantan and Pfizer/BioNTech vaccines (60.47% and 73.21%, respectively) (Supplementary material 1). Adverse Events reported in SIEAPV AE notifications were more frequent among pregnant and postpartum women aged 20 to 35 years old, with a mean age of 28.56 (Standard Deviation 7.2), who reported as white (42.84%) and brown (36.89%)

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

(Table 1). From a regional perspective, even excluding the state of São Paulo, the South (34.31%) and Southeast (33.79%) regions had most part of the notification from pregnant and postpartum women, although it changed according to the vaccine received: for Sinovac/Butantan the highest were noted in the South (40.64%), for Pfizer/BioNTech in the Southeast (45.45%), for AstraZeneca in the South (35.75%) and for Janssen in the Northeast (46.67%). According to the maternal situation, few women reported as being at postpartum (1.53%) and the distribution within the three trimesters of pregnancy were similar (25.34% in the first, 30.01% in the second and 32.82% in the third trimester of pregnancy) (Table 1). Incidence of adverse events The overall incidence of AE among pregnant and postpartum women was 309.4 / 100,000 doses of vaccines administered (95% CI 297.23, 321.51). In the analysis according to the maternal situation, IR by pregnant women was 404.3 / 100,000 doses (95% CI 388.75, 420.75) and by postpartum 19.6 / 100,000 doses (95% Cl 13.47, 25.78). Regarding the four vaccines available in the country, Sinovac/Butantan vaccine had the lowest IR (74.08 / 100,000 doses; 95% CI 63.47, 84.69) (Table 2). Stratifying the AE according to type, among pregnant women, systemic events were the most frequent notified (82.03%), followed by local (11.93%) and maternal (4.78%), being most of them classified as non-severe (90.65%) (Supplementary appendix 2). Also, the IR of systemic events in the Brazilian pregnant women was the highest (249.88/100,000 doses: 95% CI 238.97, 260.8). Maternal AE IR was 14.56/100,000 doses (95% CI 11.92, 17.2) (Table 3). The most common maternal AE notified by pregnant and postpartum women included spontaneous abortion (2.37%) pregnancy bleeding (0.76%) and neonatal death (0.52%). Among the non-maternal AE, headache (18.54%), fever (13.79%), myalgia (10.30%) and pain (7.60%) were the most reported. The

153

154

155

156

157 158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

most frequent AE were similar among the four vaccines, except for pain, which was less frequent reported for those who received Sinovac/Butantan vaccine (Table 4). Regarding the case evolution of the events, 53.30% were missing and 30.85% reported as being cured without sequelae (Supplementary material 3). Discussion In the COVID-19 pandemic reality, despite the recognition of the need for inclusion of pregnant and postpartum women in clinical trials, the speed at which the COVID-19 vaccines were developed, and trials conducted precluded inclusion of them. ²⁰ In that sense, post authorization safety studies are a way to provide more evidence for this population. Using surveillance data, we found more than 3,000 events notifications by pregnant and postpartum women after receiving at least one dose of a COVID-19 vaccine in the early stage of the campaign in Brazil. AE were the most common, although for some vaccines IE were more frequent – which may reflect the changes in recommendation to vaccinate this group disposed by the Brazilian MoH. 8,21 Concerning the frequency of AE, the distribution according to the age and race/ethnicity was similar within all vaccines available. However, in a regional perspective, it differed as each region/state could have differences in the cold chain distribution strategies. 8 Among the maternal population, pregnant women were responsible for most of the notifications reported in the period. The overall incidence of AE found for this population was 309.4/100,000 doses. Although there is a lack of evidence regarding the safety of these vaccines in the maternal population, our findings are in accordance with the available literature for other studies that assessed safety of COVID-19 in different

populations groups. An epidemiological bulletin from the Brazilian MoH from January to February of

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

2021 showed a 350.9 AEFI notifications/ 100,000 doses of vaccines early administered in the Brazilian population. ²² Another study conducted in Minas Gerais state that assessed safety of COVID-19 vaccines from January to March 2021 found an incidence rate of 777.12 AEFI per 100,000 doses applied, with 97% of them classified as non-severe AE.²³ In relation to the magnitude of our findings when compared to other vaccines recommended to pregnant and postpartum women in Brazil, a study from Silveira IO et al, assessing adverse events from the SI-EAPV database from 2015 to 2019 in Minas Gerais state, found an overall incidence of 76.9 AEFI notifications/100,000 doses.²⁴ Findings related to race/ ethnicity, type of event and case evolution were also similar to the patterns found in our results.²⁴ As for the systemic events found in our study, the most frequent types follow a similar pattern described by Gattás VL, et al in relation to the ones found for influenza vaccine, which is recommended for any gestational age in Brazil, as COVID-19 vaccines are. 25 Although we have not compared pregnant to nonpregnant women, there are studies suggesting that the physiologic changes in pregnancy seems to not materially affect non-maternal events. 26,27 Additionally, our study describes with more emphasis systemic events classified as maternal, showing an incidence of 14.56 AE notifications/ 100,000 doses, of which spontaneous abortion was the most frequent type of event (2.37%) and with differences in the frequency found for the different types of vaccines available. Brazilian data up to 2019 showed a proportion of 3.4% of spontaneous abortion in the country. Meanwhile, spontaneous abortion incidence in the literature varies from 6.5% to 21% of pregnancies, and it is recognized as one of the most common complications during a pregnancy. ^{28–30} In addition, a study assessing safety of mRNA COVID-19 vaccines in pregnant population in the United States assessed by the V-Safe pregnancy registry system found an overall frequency of spontaneous abortion of 12.6% among pregnant women who received a COVID-19 vaccines. ²⁶ Cardoso BB et al³¹,

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

however, argues that data on abortion and its complications may be incomplete in Brazil, since the hospitalizations occurred due to an abortion is only one data source to estimate the total number of abortions in the country. 31 When comparing the different vaccines administered in this population in Brazil, we found that Sinovac/Butantan and Pfizer/BioNTech vaccines had the lowest IR of AE, which is in line with MoH recommendations to only administer them in pregnant and postpartum woman. 8,32 Our study has some limitations. The AEFI notifications used in this study are subject to limitations of passive surveillance system. This means that each health level routinely and periodically sends information about the events subject to surveillance at the immediately superior. In the same way, the classifications in the database might be susceptible to the interpretation of the person filling out the system, implying in the possibility of lack of uniformity in reporting the characteristics of the event and in the place where the information is filled in the form of the surveillance system. Although these systems generate valuable information regarding the description of the occurrence of adverse events, they usually do not allow establishing causality between the occurrence of AEFI and the vaccine. 11,33-35 In that sense, our study is unable to evaluate AE outcomes that might occur in association with exposures earlier in pregnancy or postpartum period. Furthermore, the definition of postpartum women varied in the data sources used - which may underestimate the incidence in this population. In the same direction, the Brazilian obstetric observatory for COVID-19 has been showing that there are inconsistencies in the vaccination information fulfilling, since they found pregnant and postpartum women of male sex, and AEFI notified

for COVID-19 vaccines administered previous to the vaccination campaign start and over 55 years old.⁴

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

Another potential limitation of our analyses is the underreporting of AE. SIEAPV is a passive surveillance system. Underreporting can occur due to difficulties in the conclusion of cases investigations and in adherence of the population to notify the events. In that sense, mild to moderate events might be more underreported than severe that required hospitalization or more intensive care. On the other hand, each of the four vaccines were available in different moments (Sinovac/Butantan and AstraZeneca since January, Pfizer/BioNTech since May and Janssen since July 2021).8 The Janssen vaccine was first provided to the population when there was already the recommendation not to vaccinate pregnant and postpartum women with viral vector vaccines, which led to a small number of doses administered in this population, hence, a low number of notifications up to the cut-off period of this study. In the same sense, Sinovac/Butantan and AstraZeneca vaccines were available in the beginning of the campaign, when only women with comorbidities were being vaccinated. 8 Also, some of the AE presented in this study might be still under investigation during the study period and might not have a final classification. Nevertheless, our study allows a better understand of COVID-19 vaccines safety profile under a vaccination campaign placed during a pandemic setting in a LMIC as Brazil. We found a similar pattern of AE as stated in other studies, with even better results for non-viral vector vaccines, corroborating that vaccination of this groups should continue as a priority. Further studies appraising a longer time for a better understanding adverse events incidence in relation to second and booster doses and the component of vaccine interchangeability are still needed to provide a broader safety aspect for the vaccines currently under use for this population.

AJLA, YPQ and GSJ conceptualized the study. RGP, RVF, AJLA and CZD analyzed the data. RGP and RVF curated the data. AJLA, YPQ, CZD and GSJ wrote the first draft of the manuscript. YPQ, XM, WDY and other authors reviewed and edited revisions of the manuscript, had full access to all the data in the study, and had final responsibility for the decision to submit for publication.

Declaration of interests

RGP, RVF, AJLA, GSJ and CZD are employees of IQVIA Brazil which was contracted by Sinovac Life Sciences to conduct the study.

YPQ, XM, WDY are employees of Sinovac Life Sciences.

References References

252 1. Bchetnia M, Girard C, Duchaine C, Laprise C. Journal of Infection and Public Health The outbreak 253 of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the 254 current global status. J Infect Public Health [Internet] 2020;13(11):1601–10. Available from: 255 https://doi.org/10.1016/j.jiph.2020.07.011 256 2. Roggero P, Prefumo F, Silva M, et al. Maternal and Neonatal Morbidity and Mortality Among 257 Pregnant Women With and Without COVID-19 Infection The INTERCOVID Multinational Cohort 258 Study. 2021;1–10. 259 Rasmussen SA, Kelley CF, Jamieson DJ, Horton JP. Coronavirus Disease 2019 (COVID-19) 3. Vaccines and Pregnancy What Obstetricians Need to Know. 2021;137(3):408-14. 260 261 4. Rodrigues A, Lacerda L, Francisco R. Brazilian Obstetric Observatory, arXiv Prepr 262 2021;arXiv:2105:1-19. 263 5. Heath PT, Doare K Le, Khalil A. Inclusion of pregnant women in COVID-19 vaccine development. Lancet Infect Dis [Internet] 2020;20(9):1007-8. Available from: http://dx.doi.org/10.1016/S1473-264 3099(20)30638-1 265 266 Quintana SM. We have Vaccine for COVID-19! What to Recommend for Pregnant Women? Rev 6. 267 Bras Ginecol e Obs 2021;43(2):81-3. Brasil. Ministério da Saúde. NOTA TÉCNICA Nº 2 / 2021-SECOVID / GAB / SECOVID / MS. 2021. 268 7. Brasil. Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à COVID-19. PLANO 269 8. NACIONAL DE OPERACIONALIZAÇÃO DA VACINAÇÃO CONTRA A COVID-19. 11ª. Brasília/DF: 2021. 270 271 9. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunizações e

272		Doenças Transmissíveis. Nota técnica nº 651/2021-cgpni/deidt/svs/ms 1. 2021;4–7.
273	10.	Rodrigues NB, McIntyre RS, Lipsitz O, et al. A simplified 6-Item clinician administered dissociative
274		symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine
275		infusions. J Affect Disord 2021;282:160–4.
276	11.	Development P. Maternal Immunization Safety Monitoring in Low- and Middle-Income
277		Countries 2: A Roadmap for Program Development Building an approach that is practical,.
278	12.	Moura ADA, Rouberte ESC, Lima FET, Chaves CS, Canto SVE, Lima GG de. Sistema de Informação
279		de Eventos Adversos Pós-Vacinação (SI-EAPV): vantagens e desafios / Post-Vaccination Adverse
280		Event Information System (SI-EAPV): advantages and challenges. Brazilian J Heal Rev
281		2020;3(5):15610–22.
282	13.	Fala.BR - Plataforma Integrada de Ouvidoria e Acesso à Informação [Internet]. Available from:
283		https://www.gov.br/acessoainformacao/pt-br/falabr
283	14.	https://www.gov.br/acessoainformacao/pt-br/falabr BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from:
	14.	
284	14.	BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from:
284 285	14.	BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-
284 285 286	14. 15.	BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-
284 285 286 287		BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-no-11.pdf/view
284 285 286 287		BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e- monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia- no-11.pdf/view BRASIL. Ministério da Saúde. SISTEMA DE INFORMAÇÕES DO PROGRAMA NACIONAL DE
284 285 286 287 288 289	15.	BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e- monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia- no-11.pdf/view BRASIL. Ministério da Saúde. SISTEMA DE INFORMAÇÕES DO PROGRAMA NACIONAL DE IMUNIZAÇÕES EVENTOS ADVERSOS PÓS-VACINAÇÃO: Manual do usuario. 2003.
284 285 286 287 288 289	15.	BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e- monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia- no-11.pdf/view BRASIL. Ministério da Saúde. SISTEMA DE INFORMAÇÕES DO PROGRAMA NACIONAL DE IMUNIZAÇÕES EVENTOS ADVERSOS PÓS-VACINAÇÃO: Manual do usuario. 2003. Brasil. Ministério da Saúde. Campanha Nacional de Vacinação contra Covid-19 [Internet]. [cited]

294		2. 2020;(December).
295	18.	Brasil. Presidência da República. Lei Geral de Proteção de Dados Pessoais (LGPD). Brasil: 2018.
296	19.	Brasil. Conselho Nacional de Saúde. RESOLUÇÃO N° 510, DE 07 DE ABRIL DE 2016 O. 2016.
297	20.	Craig AM, Hughes BL, Swamy GK. Expert Review Coronavirus disease 2019 vaccines in pregnancy.
298		Am J Obstet Gynecol MFM [Internet] 2021;3(2):100295. Available from:
299		https://doi.org/10.1016/j.ajogmf.2020.100295
300	21.	Brasil. Ministério da saúde. secretaria de Vigilância em saúde. Boletim epidemiológico especial.
301		Doença pelo Novo Coronavírus – COVID-19 [Internet]. 2021. Available from:
302		https://www.gov.br/saude/pt-
303		br/media/pdf/2021/novembro/26/boletim_epidemiologico_covid_90_26nov21_eapv3b.pdf
304	22.	Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Situação epidemiológica dos
305		eventos adversos pós-vacinação contra a covid-19, Brasil, 2021. 2021;52.
306	23.	Silva RB da, Silva TPR da, Sato APS, et al. Adverse events following immunization against SARS-
307		CoV-2 (covid-19) in the state of Minas Gerais. 2021;2:1–10.
308	24.	Oliveira PMN de, Lignani LK, Conceição DA da, et al. O panorama da vigilância de eventos
309		adversos pós-vacinação ao fim da década de 2010🏿: importância , ferramentas e desafios
310		Surveillance of adverse events following immunization in the late 2010s1: an overview of the
311		importance , tools , and challenges El. 2020;
312	25.	Gattás VL, Braga PE, Koike ME, et al. Safety assessment of seasonal trivalent influenza vaccine
313		produced by Instituto Butantan from 2013 to 2017. J São Paulo Inst Trop Med 2018;(November
314		2018):1–8.

315	26.	Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety
316		in Pregnant Persons. N Engl J Med 2021;384(24).
317	27.	Riley LE. Edit or i a l s mRNA Covid-19 Vaccines in Pregnant Women. 2021;2342–3.
318	28.	Rodini ESO, Tsuribe PM, Maria L, Moreira V, Oliveira M De, Capannacci J. Abortamentos
319		espontâneos 🗈 : estudos citogenéticos e riscos de recorrência Spontaneous abortions 🗈 :
320		cytogenetic studies and risks of occurrence. 2004;11(1):50–2.
321	29.	Zheng D, Li C, Wu T, Tang K. Factors associated with spontaneous abortion: a cross-sectional
322		study of Chinese populations. Reprod Health [Internet] 2017;14(1):33. Available from:
323		http://reproductive-health-journal.biomedcentral.com/articles/10.1186/s12978-017-0297-2
324	30.	Fergusson DM, John Horwood L, Ridder EM. Abortion in young women and subsequent mental
325		health. J Child Psychol Psychiatry [Internet] 2006;47(1):16–24. Available from:
326		https://onlinelibrary.wiley.com/doi/10.1111/j.1469-7610.2005.01538.x
327	31.	Cardoso BB, Saraceni V. Abortion in Brazil: what do the official data say? 2020;1–13.
328	32.	Brasil. Ministério da Saúde. Manual de vigilância epidemiológica de eventos adversos pós-
329		vacinação. Brasília: 2021.
330	33.	Silveira IO da, Silva TPR da, Oliveira BM, et al. Adverse events following immunization in pregnant
331		women from Minas Gerais. 2021;1–10.
332	34.	Brasil. ANVISA. Plano de Monitoramento de Eventos Adversos de Medicamentos e Vacinas Pós-
333		Autorização de Uso Emergencial 🛽 : Diretrizes e Estratégias de Farmacovigilância para o
334		enfrentamento da COVID-19. 2021.
335	35.	Pacheco F, Domingues C, Maranhão A, et al. Análise do Sistema de Informação da Vigilância de

Eventos Adversos Pós-Vacinação no Brasil, 2014 a 2016. Rev Panam Salud Pública [Internet] 2018;1–8. Available from: http://iris.paho.org/xmlui/handle/123456789/34861

336

337

1 Tables

Table 1. Sociodemographic characteristics of pregnant and postpartum women that notified adverse events after receiving vaccines against

COVID-19

	Sinovac/Butantan		Pfizer/BioNTech		AstraZeneca ¹		Jan	ssen	Tota	al
	AE	%	AE	%	AE	<u></u> %	AE	<u></u> %	AE	<u></u> %
	(n= 187)	70	(n= 572)	76	(n= 1712)	70	(n= 15)	76	(n= 2,486)	70
Age group (years	old)									
<15	0	0.0%	6	1.05%	5	0.29%	0	0.0%	11,00	0.44%
16 to 20	18	9.63%	76	13.29%	180	10.51%	2	13.33%	276,00	11.1%
21 to 25	47	25.13%	127	22.2%	460	26.87%	7	46.67%	641,00	25.78%
26 to 30	47	25.13%	101	17.66%	438	25.58%	3	20.0%	589,00	23.69%
31 to 35	51	27.27%	159	27.8%	398	23.25%	0	0.0%	608,00	24.46%
36 to 40	15	8.02%	68	11.89%	184	10.75%	0	0.0%	267,00	10.74%
11 to 45	8	4.28%	29	5.07%	20	1.17%	3	20.0%	60,00	2.41%
16 to 50	1	0.53%	1	0.17%	0	0.0%	0	0.0%	2,00	0.08%
>50	0	0.0%	5	0.87%	26	1.52%	0	0.0%	31,00	1.25%
nconsistent ²	0	0.0%	0	0.0%	1	0.06%	0	0.0%	1,00	0.04%

Race/ethnicity										
White	70	37.43%	222	38.81%	770	44.98%	3	20.0%	1065	42.84%
Black	12	6.42%	46	8.04%	80	4.67%	0	-	138	5.55%
Yellow	1	0.53%	2	0.35%	7	0.41%	0	-	10	0.4%
Brown	79	42.25%	220	38.46%	608	35.51%	10	66.67%	917	36.89%
Indigenous	1	0.53%	0	-	1	0.06%	0	-	2	0.08%
lgnored	24	12.83%	82	14.34%	246	14.37%	2	13.33%	354	14.24%
Region of notification										
South	76	40.64%	162	28.32%	612	35.75%	3	20.0%	853	34.31%
Southeast	53	28.34%	260	45.45%	524	30.61%	3	20.0%	840	33.79%
North	14	7.49%	32	5.59%	70	4.09%	0	-	116	4.67%
Northeast	21	11.23%	90	15.73%	347	20.27%	7	46.67%	465	18.7%
Midwest	23	12.3%	28	4.9%	159	9.29%	2	13.33%	212	8.53%
Maternal situation										
1st trimester	76	40.64%	173	30.24%	368	21.5%	13	86.67%	630	25.34%
2nd trimester	43	22.99%	144	25.17%	557	32.54%	2	13.33%	746	30.01%
3rs trimester	45	24.06%	163	28.5%	608	35.51%	0	-	816	32.82%
Postpartum	8	4.28%	12	2.1%	18	1.05%	0	-	38	1.53%
Inconsistent ³	10	5.35%	72	12.59%	136	7.94%	0	-	218	8.77%

lgnored ⁴		5	2.67%	8	1.4%	25	1.46%	0	-	38	1.53%
----------------------	--	---	-------	---	------	----	-------	---	---	----	-------

AE: Adverse Event; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152; ²Ages unlikely to conceive a pregnancy were considered as inconsistent;

8 Table 2. Incidence of adverse events notified by Brazilian pregnant and postpartum women by vaccine received

			Overall			Pregnant					Postpartum en			
	AE	N doses	IR*	95% CI	AE	N doses	IR*	95% CI	AE	N doses	IR*	95% CI CC-		
Sinovac/Butantan	187	252430	74.08	(63.47, 84.69)	179	193517	92.5	(78.95, 106.04)	9	58913	15.28	(5.3, 25.26)		
Pfizer/BioNTech	572	484310	118.11	(108.43, 127.78)	560	372980	150.14	(137.72, 162.57)	12	111330	10.78	(4.68, 16.88		
Astra Zeneca ¹	1712	65435	2616.34	(2494.04, 2738.64)	1694	37954	4463.3	(4255.55, 4671.04)	18	27481	65.5	(35.25, 95.75		
Janssen	15	1388	1080.69	(536.76, 1624.62)	15	367	4087.19	(2061.54, 6112.85)	0	1021	0	(0.0, 0.0) E		
Total	2486	803563	309.37	(297.23, 321.51)	2448	604818	404.75	(388.75, 420.75)	39	198745	19.62	(13.47, 25.78)		

⁹ AE: Adverse Events; IR: incidence rate; CI: Confidence interval;

7

11 N.B: Pregnant women can be breastfeeding; hence, they will count in pregnant and postpartum columns.

^{5 &}lt;sup>3</sup>Gestational ages inconsistent with a pregnancy i.e.: 12 months ⁴Stated as ignored in the notification.

^{*} Due to lack of notifications in the State of São Paulo, the Southeast region will include the States of Rio de Janeiro, Espírito Santo and Minas Gerais;

^{*} IR per 100,00 doses; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152;

Table 4. Frequency of most common adverse events experienced by pregnant and postpartum women receiving COVID-19 vaccines and who

16 reported an AEFI

	Sinovac/Butantan		Pfizer/BioNTech		AstraZeneca ¹		Janssen		Total	
	AE		AE		AE		AE		AE	
	(n= 187)	%	(n= 572)	%	(n= 1712)	%	(n= 15)	%	(n=2,486)	%
Maternal										
Spontaneous abortion	9	4.81%	28	4.9%	21	1.23%	1	0.066%	59	2.37%
Pregnancy bleeding	6	3.21%	3	0.52%	11	0.64%	0	0%	20	0.80%
Neonatal death	3	1.6%	9	1.57%	1	0.06%	0	0%	13	0.52%

¹³ IR: incidence rate; CI: confidence interval; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152;

^{14 *}IR *per* 100,000 doses administered.

Premature birth	1	0.53%	3	0.52%	3	0.18%	0	0%	7	0.28%
Abdominal pregnancy	3	1.6%	0	0%	0	0%	0	0%	3	0.12%
Non-maternal										
Headache	20	10.7%	77	13.46%	360	21.03%	4	28.57%	461	18.54%
Fever	13	6.95%	46	8.04%	282	16.47%	2	14.29%	343	13.8%
Myalgia	12	6.42%	37	6.47%	206	12.03%	1	7.14%	256	10.3%
Pain	3	1.6%	35	6.12%	149	8.7%	2	14.29%	189	7.6%
Vomit	2	1.07%	20	3.5%	67	3.91%	2	14.29%	91	3.66%
Chills	4	2.14%	8	1.4%	77	4.5%	0	0%	89	3.58%
Nausea	2	1.07%	19	3.32%	62	3.62%	1	7.14%	84	3.38%
Abdominal pain	9	4.81%	22	3.85%	44	2.57%	1	7.14%	76	3.06%
Diarrhea	3	1.6%	20	3.5%	40	2.34%	0	0%	63	2.53%
Arm Pain	0	0%	26	4.55%	34	1.99%	0	0%	60	2.41%
Asthenia	6	3.21%	15	2.62%	35	2.04%	0	0%	56	2.25%
Fatigue	2	1.07%	14	2.45%	39	2.28%	0	0%	55	2.21%
Cough	7	3.74%	28	4.9%	17	0.99%	0	0%	52	2.09%
Dyspnea	5	2.67%	15	2.62%	31	1.81%	0	0%	51	2.05%
Runny nose	7	3.74%	23	4.02%	16	0.93%	0	0%	46	1.85%
Sore throat	4	2.14%	11	1.92%	22	1.29%	0	0%	37	1.49%

Edema 4 2.14% 9 1.57% 14 0.82% 0 0% 27 1.09%

AE: Adverse event; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152.

Figures 2

3 Figure 1. Attrition diagram

